M. Lacroix-Triki

340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

Barbara Pistilli, Luisa Pierotti, M. Lacroix-Triki et al. · Annals of Oncology · 2024 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

B. Pistilli, Nusaïbah Ibrahimi, M. Lacroix-Triki et al. · ESMO Open · 2023 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

M.F. Mosele, Amélie Lusque, Véronique Dièras et al. · Annals of Oncology · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacology +14

High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome

Véronique D’Hondt, M. Lacroix-Triki, Marta Jarlier et al. · Oncotarget · 2017 · 11 citations · Full text

Medicine, Oncology, Pathology +17